Advice
following a full submission
edoxaban (Lixiana®) is accepted for use within NHS Scotland.
Indication under review: Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.
One phase III study showed non-inferiority of edoxaban versus a vitamin K antagonist for venous thromboembolism recurrence in patients who had received at least five days treatment with low molecular weight heparin or unfractionated heparin. Edoxaban was also associated with a significant reduction in the risk of major and clinically relevant non-major bleeding (composite endpoint).
Download detailed advice193KB (PDF)
Medicine details
- Medicine name:
- edoxaban (Lixiana)
- SMC ID:
- 1090/15
- Indication:
- Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.
- Pharmaceutical company
- Daiichi Sankyo UK Ltd
- BNF chapter
- Cardiovascular system
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 09 November 2015